Pharmaceutical 99% Purity Everolimus Raw Material Powder CAS 159351-69-6 Everolimus

• CAS No.: 159351-69-6
• Formula: C53h83no14
• EINECS: 621-003-9
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Refined
• Model NO.: HRK-Everolimus
• Colour: White
• Product Name: Everolimus
• Sample: Everolimus Valiable
• Mf: C53h83no14
• Certificate: GMP ISO USP Bp
• Assay: 99%Min, 98.0% --101.0%
• Test: HPLC
• Grade Standard: Food Grade, Medicine Grade
• Type of Product: Auxiliaries and Other Medicinal Chemicals
• Storage: Cool Dry Place
• Shelf Life: 2 Years Proper Storage
• Application: Vertinary Raw Materials
• CAS: 159351-69-6
• Molecular Weight: 958.22400
• Brand Name: Henrikang
• Transport Package: 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
• Specification: 99%
• Trademark: Henrikang
• Origin: Shaanxi China
• Production Capacity: 500000kg/Year

Product Description

 Pharmaceutical 99% Purity Everolimus Raw Material Powder CAS 159351-69-6 Everolimus

Product name	China Price Pure Everolimus 99% CAS 159351-69-6 Everolimus Powder
CAS No.	159351-69-6
Einecs No	N/A
Appearance	white powder
Storage Temperature	Keep in a cool, dry, dark location in a tightly sealed container or cylinder.

Solubility:Soluble in ,, DMSO (100mg/ml), water (<1mg/ml, 25c), ethanol (100mg/ml)

Usage:Animal Pharmaceuticals

Everolimus, an orally adminstered rapamycin analog, has recently been approved by the FDA for treatment of renal cell
carcinoma (RCC) refractory to inhibitors of vascular endothelial  () receptor signaling. Everolimus
significantly increased progression-free survival (median PFS for the everolimus treated group was 4.0 months versus
1.9 months for the placebo group), although tumor regressions were observed only infrequently.


While the target for everolimus, (the serine/threonine kinase mTOR) is well established, the mechanism by which this
agent retards tumor growth is not well defined. Further, biomarkers that predict tumor sensitivity are still elusive. The
mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed.

Function of Everolimus


Everolimus may have a role in heart transplantation, as it has been shown to reduce chronic allograft vasculopathy in
 such transplants. It also may have a similar role to sirolimus in kidney and other transplants.

Although, sirolimus had generated fears over use of m-TOR inhibitors in liver transplantation recipients, due to possible
early hepatic artery thrombosis and graft loss, use of everolimus in the setting of liver transplantation is promising. Jeng
et al., in their study of 43 patients, concluded the safety of everolimus in the early phase after living donor liver
transplantation. In their study, no hepatic artery thrombosis or wound infection was noted. Also, a possible role of
everolimus in reducing the recurrence of hepatocellular carcinoma after liver transplantation was correlated. A target
trough level of 3 ng/mL at 3 months was shown to be beneficial in recipients with pre-transplant renal dysfunction. In
their study, 6 of 9 renal failure patients showed significant recovery of renal function, whereas 3 showed further
deterioration, one of whom required hemodialysis.